Beta-2 Microglobulin dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Beta-2 Microglobulin is a blood protein that rises with age. Injected into young mice, it harms new brain cell growth and memory. In people it is a long-standing hospital blood test and goes with worse thinking scores. Nobody has tried lowering it for ageing.
Evidence grade for Beta-2 Microglobulin: Preliminary. The rule: studied in people, but no published study has had people take it. The sum on this page: 1 human study where nobody was given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 0
- Found nothing
- 0
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
1 human study where nobody was given it
5 effects reported, 4 unwanted, 1 wanted, by people using it, not a trial
Goal pages: Brain, memory and mood
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
This is a blood protein that rises with age. It is part of the system every cell uses to show the immune system what is inside it. Injected into young mice, it harms memory.
What people take it for
- Nothing. This is one people want lowered, not raised.
- Tracking it as an ageing marker.
What studies in people showed
No trial has tested lowering this for ageing or thinking in a person. What we have is watching. In 1,267 US adults aged 60 and over, higher levels went with worse scores on a timed thinking test and a faster pace of ageing reading. Everything was measured at one moment. In mice, the evidence runs both ways. Injecting it harmed memory and slowed new brain cell growth in young animals. Mice bred without it did not show the usual decline with age. A later paper found it blocks a key receptor for learning.
What people report
Reports, not study results
The good
- We have not collected user reports on this one yet.
- It is easy to measure. Any hospital lab can run it.
The bad
- It rises as kidney function falls, and poor kidney function itself goes with worse thinking. So the link may not be about this protein.
- In people on long term dialysis it builds up and forms deposits in joints and tissues.
- It is a fixed part of every immune display molecule. Stripping it out would hit the immune system.
- Nobody has lowered it in a person to see what happens.
Where these come from: The survey numbers, the dialysis illness and the mouse results all come from the studies on this page. No user reports exist.
My bottom line
A marker worth tracking, not a target you can act on. If yours is high, ask about your kidneys first.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Animal and lab work, not yet tested in people
Real results, but from animals or cells, not people. What works in a mouse often does not work the same way in a person. Nobody can patent this, so nobody would ever earn back the cost of a study in people. That is usually why there is none. The record on this one is set out below.
- Memory and thinking2 animal or lab studies
35 of the 36 indexed goals have no study of any kind behind Beta-2 Microglobulin
No study in people, animals or cells on this page reports a result for these. That does not prove Beta-2 Microglobulin does nothing for them. It does mean anything you have heard about Beta-2 Microglobulin and one of these did not come from a study cited here.
Show full evidence
What is Beta-2 Microglobulin?
Beta-2 Microglobulin is a blood protein that rises with age. Injected into young mice, it harms new brain cell growth and memory. In people it is a long-standing hospital blood test and goes with worse thinking scores. Nobody has tried lowering it for ageing.
The human evidence is from watching, not treating. A 2025 analysis looked at 1,267 US adults aged 60 and over from a national health survey run between 1999 and 2002. Higher B2M went with worse scores on a timed thinking test and with a faster reading on a pace-of-ageing measure. That pace measure accounted for about a tenth of the link. B2M is also a long-standing medical molecule in its own right. It is the protein that builds up and forms deposits in people on long-term dialysis for kidney failure.
No trial has tested lowering B2M for ageing or thinking in a person.
Beta-2 microglobulin is part of a molecule that every cell uses to show the immune system what is inside it. Everyone has it in their blood. A 2015 Nature Medicine paper named it as an ageing factor carried in the blood. B2M is higher in the blood of ageing people and mice, and in the memory centre of old mice. When B2M was injected into young mice, either into the body or straight into the memory centre, it harmed their memory and slowed new brain cell growth. Mice bred without B2M did not show the usual memory decline with age, and grew more new brain cells in old age. The harm was partly reduced in mice with less of that immune-display molecule on their cell surfaces.
A 2023 Cell paper added a mechanism, from an unexpected direction. Studying Down syndrome, the authors found factors in the blood driving problems at the junctions between nerve cells. They found more B2M in the blood of people with Down syndrome. Giving B2M to ordinary mice caused the same junction and memory problems. Removing it, either by breeding or with an antibody, undid them. B2M works by blocking a key receptor for learning, the NMDA receptor, by grabbing one loop of it. Peptides that compete for that loop restored normal function.
How does Beta-2 Microglobulin work?
In mice, B2M given into the body or straight into the memory centre harms memory and new brain cell growth. The harm is partly reduced in mice with less of the immune-display molecule on their cell surfaces. The 2023 work shows B2M acts as the body's own blocker of the NMDA receptor, a key receptor for learning, by grabbing one loop of it. Peptides that compete for that loop restore normal function. In people, B2M's known jobs are in the immune system and the kidney. It is a fixed part of every MHC class I molecule, the immune-display system. The kidney clears it. In people on long-term dialysis it builds up and forms deposits. The brain receptor mechanism has not been shown in a person.
What have studies in people found about Beta-2 Microglobulin?
From watching, and fairly large for this field. B2M rises with age in human blood, and in 1,267 older US adults higher levels went with worse thinking scores and a faster measured pace of ageing. B2M also causes a well known illness of its own in kidney failure. Nobody has been given anything to lower B2M for ageing or thinking.
- National survey analysis (Frontiers in Aging Neuroscience 2025): 1,267 adults aged 60 and over. Higher B2M went with lower scores on a timed thinking test and with a faster pace-of-ageing reading, after allowing for other differences, and the pattern held across smaller groups. Everything was measured at one moment, so which way cause runs cannot be told.
- B2M is higher in the blood of ageing people, reported in the 2015 Nature Medicine paper alongside the mouse work.
- Protein screening of blood from people with Down syndrome found more B2M. That was the starting point for the 2023 brain receptor paper.
- Known medical background: the kidney clears B2M. It builds up in people on long-term dialysis and forms deposits in the joints and tissues. It is also used as a routine blood test in kidney and blood medicine.
- No trial of lowering or blocking B2M for ageing or thinking is registered or published.
What this does not tell you: The survey link was measured at one moment and cannot separate cause from result. B2M also rises as kidney function falls, and poor kidney function itself goes with worse thinking and with age. The pace-of-ageing measure explaining about a tenth of the link is a very rough estimate, with a range running from almost nothing to nearly half. Nobody has lowered B2M in a person to see what happens. And because B2M is a fixed part of every immune-display molecule, blocking it across the body would affect the immune system in ways no study has looked at.
The state of the research
The mouse evidence for B2M runs both ways, which is unusual here. Adding it harmed memory and new brain cell growth in young animals. Removing it stopped the usual decline in old ones. That is stronger than a study that only finds a link. It is still mice.
The reason there is no programme in people is built into the protein, not into the money. B2M is not an optional signal floating in the blood. It is a fixed part of every MHC class I molecule, on every cell with a nucleus. Lowering it across the body means interfering with how cells show the immune system what is inside them. That is why the ideas in the research are narrower: an antibody, or the competing peptides that block the one specific brain receptor interaction found in 2023, rather than stripping the protein out. None of those has been tested in a person.
One correction is worth recording for anyone tracing this work. The 2023 Cell paper is often listed as the B2M ageing paper. It is not. It is a Down syndrome study, and what it adds is the brain receptor mechanism. The ageing paper is the 2015 Nature Medicine one.
The evidence, in charts
Fig. 1a · how many people
1,267people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| Frontiers in Aging Neuroscience 2025 | 1,267 | 100% |
The whole total is one study of 1,267. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
1 of 4 sources here is a study in people. The rest are not.
- Study in people · done in people125%
- Animal study · done in animals250%
- Review of studies · sums up other studies125%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 4 different years, 2015 to 2025, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Biologic
- Molecule weight
- Not on file
- Half-life
- None on file
- Chain length
- None on file
No amino acid sequence is on file for Beta-2 Microglobulin, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2025beta2-microglobulin and cognitive decline: unraveling the mediating role of the Dunedin Pace of Aging methylation
Nobody was given anything, and the study cannot show what causes what. 1,267 US adults aged 60 and over had beta-2 microglobulin measured in a national health survey. Higher levels went with worse scores on a timed thinking test and with a faster reading on a pace-of-ageing measure. That pace measure accounted for roughly a tenth of the link. Everything was measured at one moment, so a higher level could be a cause, a consequence, or neither.
1,267 US adults aged 60 and over from NHANES 1999 to 2002. After adjusting for all confounders, each one-unit increase in log-transformed B2M was associated with a 5.13 point lower Digit Symbol Substitution Test score (95 percent CI -9.03 to -1.24) and a 0.04 higher Dunedin Pace of Aging methylation value (95 percent CI 0.01 to 0.07). That pace measure mediated 9.0 percent of the association (95 percent CI 0.1 to 43.2 percent). Cross-sectional and observational.
- Review of studies2016Dialysis-related amyloidosis: challenges and solutions
A medical review of the illness in which beta-2 microglobulin builds up in people on long-term dialysis and forms deposits in their joints and tissues. That is the known harm from B2M building up in people, and it is not an ageing study.
Human clinical review of dialysis-related amyloidosis, the condition in which beta-2 microglobulin accumulates and deposits as amyloid in people with long-term kidney failure. This is the established human pathology of B2M accumulation, and it is not an ageing study.
- Animal study2015beta2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis
In mice, with one human measurement. B2M is higher in the blood of ageing people and mice, and in the memory centre of old mice. Injected into young mice, it harmed memory and slowed new brain cell growth. The harm was partly reduced in mice carrying less of the immune-display molecule. Mice bred without B2M kept their memory as they aged and grew more new brain cells when old. Funded by the US National Institutes of Health.
Mouse, with human measurement. B2M is elevated in the blood of ageing humans and mice and in the hippocampus of aged mice and young heterochronic parabionts. Exogenous B2M injected systemically or into the hippocampus impaired hippocampal-dependent cognition and neurogenesis in young mice, partly mitigated in mice with reduced cell-surface MHC class I. Absence of endogenous B2M abrogated age-related cognitive decline and enhanced neurogenesis in aged mice. NIH funded.
- Animal study2023beta2-microglobulin functions as an endogenous NMDAR antagonist to impair synaptic function
In mice, with protein screening of human blood, and in Down syndrome rather than ageing. Blood factors were shown to cause problems at the junctions between nerve cells. There was more B2M in the blood of people with Down syndrome. Giving B2M to ordinary mice caused the same junction and memory problems. Breeding it out, or using an antibody, undid them. B2M blocks a key learning receptor by grabbing one loop of it.
Mouse, with human plasma proteomics, in Down syndrome rather than in ageing. Parabiosis and plasma infusion showed blood-borne factors drive synaptic deficits in Down syndrome models. B2M was elevated in human Down syndrome plasma; systemic B2M produced synaptic and memory defects in wild-type mice; genetic deletion or an anti-B2M antibody counteracted the impairments. B2M antagonises NMDA receptor function via the GluN1-S2 loop, and competitive peptides restored receptor-dependent function.
Common questions
Has Beta-2 Microglobulin been tested in people?
Not in a completed trial cited here. 1 human study where nobody was given it. Beta-2 Microglobulin is a blood protein that rises with age. Injected into young mice, it harms new brain cell growth and memory. In people it is a long-standing hospital blood test and goes with worse thinking scores. Nobody has tried lowering it for ageing.
What is the Beta-2 Microglobulin dosage?
No human dose established. No published study on this page has given this compound to people and reported a result. 1 human study where nobody was given it
Is Beta-2 Microglobulin FDA-approved?
No therapy that lowers B2M is approved for ageing or thinking skills, and none is in a registered study for those uses. Doctors measure B2M in lab tests for kidney and blood diseases.
Does beta-2 microglobulin cause cognitive decline?
In mice, the evidence shows cause running both ways. Injecting it harmed memory and new brain cell growth in young animals, and mice bred without it did not show the usual decline with age. In people, the evidence is a link: in 1,267 adults over 60, higher B2M went with lower scores on a timed thinking test. A link found at one moment cannot show cause.
Can you lower B2M?
Not as a tested treatment. No trial of lowering or blocking B2M for ageing or thinking is registered. Because B2M is a fixed part of every immune-display molecule, stripping it out across the body would interfere with how cells show the immune system what is inside them. That is why the ideas in the research are a targeted antibody, or peptides that block one specific interaction, rather than lowering the protein.
Why is B2M measured in hospitals?
For reasons that have nothing to do with ageing. The kidney clears it, so it builds up in people with kidney failure. Over years on dialysis that build-up forms deposits in joints and tissues. It is also a routine blood test in kidney and blood medicine.